ABSTRACT
The quality of the medical care depends on numerous factors that can often be influenced by the doctor itself. It is a great challenge to follow the constant scientific progress in practice. Scientific standards in gastroenterology are defined in DGVS guidelines and regularly revised. The implementation of evidence-based recommendations in practice remains challenging. On the basis of the DGVS guidelines, the Quality Commission has therefore developed a selection of quality indicators with particular relevance using standardized criteria, the broad implementation of which could contribute to improved patient care in gastroenterology.
Subject(s)
Gastroenterology , Metabolic Diseases , Germany , Humans , Inpatients , OutpatientsABSTRACT
"Klug entscheiden" addresses the problem of over- and undersupply in medicine. Following the American model "Choosing wisely" an interdisciplinary team of all internal medicine societies develops evidence-based recommendations to improve the quality of indications. In contrast to guidelines, the initiative does not provide comprehensive medical recommendations, but focuses on problems that are particularly relevant to health care. In addition, it is intended to promote communication between doctors and patients, but also the national debate on the responsible and sensible use of medical resources.
Subject(s)
Delivery of Health Care/standards , Internal Medicine/organization & administration , Professional-Patient Relations , Societies, Medical/standards , Communication , HumansSubject(s)
Crohn Disease , Gastroenterology , Humans , Crohn Disease/diagnosis , Crohn Disease/therapy , Gastroenterology/standards , GermanyABSTRACT
This guideline provides evidence-based key recommendations for diagnosis and therapy of complications of liver cirrhosis and upgrades the 2011 version. An interdisciplinary team of medical experts and patient support groups developed the guideline following the AWMF recommendations for evidence based consensus guidelines. New chapters concerning diagnosis and therapy of hepatic encephalopathy were added.
Subject(s)
Hepatic Encephalopathy , Liver Cirrhosis , Practice Guidelines as Topic , Consensus , Gastroenterology , Hepatic Encephalopathy/diagnosis , Hepatic Encephalopathy/therapy , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/therapyABSTRACT
The DGVS aims to develop high quality clinical guidelines. Version 2 of the guideline program takes up new methodical demands to optimise the development process.
Subject(s)
Delivery of Health Care/standards , Gastroenterology/standards , Practice Guidelines as Topic , Practice Patterns, Physicians'/standards , Societies, Medical/standards , GermanySubject(s)
Gastroenterology , Gastrointestinal Diseases , Metabolic Diseases , Gastrointestinal Motility , HumansABSTRACT
Mesh biocompatibility is basically determined by the foreign body reaction (FBR). In contrast to physiological wound healing and scar formation, the FBR at the host-tissue/biomaterial interface is present for the lifetime of the medical device. The cellular interactions at the mesh/tissue interface proceed over time ending up in a chronic inflammatory process. The time course of the FBR has been studied extensively and consists of three crucial steps that are protein absorption, cell recruitment and, finally, fibrotic encapsulation and extracellular matrix formation. Each of these steps involves a complex cascade of immune modulators including soluble mediators and various cell types. Recent research has focused on the cellular and molecular interactions of the distinct phases of the FBR offering a new basis for therapeutical strategies. The highly dynamic process of the FBR is considerably influenced by the biomaterial composition. Modifications of the type of polymer, the material weight, the filament structure and the pore size are realized and have substantial effects on the in vivo biocompatibility. Moreover, modern mesh technology aims to utilize the available implants as carrier systems for bioactive drugs. Studies in animal models account for the efficiency of these drugs that aim to reduce mesh-related infections or to minimize FBR by influencing inflammation or extracellular matrix remodelling. A thorough understanding of the molecular mechanisms of FBR provides a sophisticated background for the development of new biomaterials at least as carrier systems for bioactive reagents to reduce inflammation and to improve clinical outcome.